Athyrium Capital raises $2bn

The New York-based firm will target commercial-stage healthcare companies.

ByKristian Lundberg

5 December 2017•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.